Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate

Drug Profile

Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate

Alternative Names: HENO 3; MabCD3-dgA/CD7-dgA; T-Guard

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Radboud-University-Nijmegen-Medical-Centre
  • Developer Xenikos
  • Class Drug conjugates; Immunotoxins; Lectins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Protein synthesis inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease

Most Recent Events

  • 15 May 2018 Xenikos plans a phase III registration trials for Graft-versus-host disease (Second-line therapy or greater) in European Union and USA in 2019
  • 09 Dec 2017 Xenikos plans a pivotal global controlled trial for steroid-refractory acute Graft-versus-host disease
  • 09 Dec 2017 Interim efficacy and adverse events data from a phase I/II in graft-versus-host disease presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top